Psilocybin Patents – Updates as of May 2018
A while back, we wrote an article about patenting psilocybin inventions. This topic has become more interesting because of the interests on both sides of psilocybin innovation. A growing body of scientific research suggests that psilocybin may provide substantial benefits for many people suffering from psychological disorders, such as depression an anxiety. See Journal of Psilocybin Science (Treatments) at PsilocybinTechnology.com.
A recent article by Herb.co highlights the debate over how money will affect innovation and access to psilocybin technology. (“Will psychedelics go corporate like cannabis?”) The article points to some potential conflicts over control and intellectual property.
Setting aside the issue of how corporations will affect the psilocybin space, we have kept up with our intellectual curiosity about psilocybin intellectual property. (New forms of natural products may be patentable). Recently, we noticed a few noteworthy events in the psilocybin IP space.
Psilocybin Patent Application by Paul Stamets
A patent application by Paul Stamets for “Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin” recently published.
Paul Stamets is one of the world’s leading mycologists and an expert in psilocybin containing mushrooms. He is the author of several books on the topic, including one entitled Psilocybin Mushrooms of the World.
According the the published application, Stamets’s invention relates to using psilocybin and niacin for neuroregeneration. In particular, it focuses on “neuroregenerative compositions based upon constituents isolated from or contained within mushroom fruitbodies or mycelia, or the corresponding synthetic molecules, combined with niacin.”
Psilocybin Patent Application by Compass Pathways
Compass Pathways appears to have a patent application in Great Britain for “Preparation of Psilocybin, different polymorphic forms, intermediates, formulations and their use”:
According to Google Patents GB201716505A appears to be a pending application (aka GB Patent application number GB1716505.1) with a priority date of October 9, 2017.
The Compass Pathways IP has already attracted criticism from some members of the psychedelic community. For example, the non-profit organization Chacruna, is concerned that corporate interest in psilocybin could hurt process towards psychedelic therapies. Robert Jesse of John’s Hopkins University fears that corporate influence could create a landscape “clogged by proprietary methods, restrictive licensing, exclusive contracts, patents, and the like.”